Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 10/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13399884 | 0.88 | AURKA (0.58) | AURKAAURKBHRH3CHEK2RET | |
| SCHEMBL13399877 | 0.86 | AURKA (0.47) | AURKAAURKB | |
| SCHEMBL13399889 | 0.85 | AURKA (0.52) | AURKAAURKBHRH3PPARALTA4H | |
| SCHEMBL13399887 | 0.85 | AURKA (0.56) | AURKAAURKBHRH3PPARACACNA1B | |
| SCHEMBL13399880 | 0.84 | AURKA (0.60) | AURKAAURKBHRH3PPARA | |
| SCHEMBL13430288 | 0.83 | AURKA (0.39) | AURKAAURKBHRH3CHEK2RET | |
| SCHEMBL13399854 | 0.80 | AURKA (0.62) | AURKAAURKB | |
| SCHEMBL13399878 | 0.79 | AURKA (0.76) | AURKAAURKBHRH3 | |
| SCHEMBL13399850 | 0.78 | AURKA (0.64) | AURKAAURKB | |
| SCHEMBL13399860 | 0.76 | AURKA (0.68) | AURKAAURKBCHEK2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006252-B2 | Fused multicyclic compounds as protein kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2015-04-14 | — | — | US | disclosed |
| US-9006252-B2 | Fused multicyclic compounds as protein kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2015-04-14 | — | — | US | disclosed |
| EP-2331530-B1 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | NAT HEALTH RESEARCH INSTITUTES (CN) | 2013-08-21 | — | — | EP | disclosed |
| WO-2010036629-A2 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-04-01 | — | — | WO | disclosed |
| US-20100081675-A1 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-04-01 | — | — | US | disclosed |
| US-20100081675-A1 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081675-A1 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | AURKC, AURKA, AURKB | AURKA 2/4885AURKB 3/4885HRH3 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.